BTEKL Stock Overview
An exchange traded fund launched by BlackRock Asset Management Ireland Limited.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
iShares IV Public Limited Company - iShares NASDAQ US Biotechnology UCITS ETF Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.12 |
52 Week High | US$5.12 |
52 Week Low | US$5.12 |
Beta | 0 |
11 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 0% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
BTEKL | GB Capital Markets | GB Market | |
---|---|---|---|
7D | 0% | 2.7% | 1.7% |
1Y | n/a | 19.1% | 8.9% |
Return vs Industry: Insufficient data to determine how BTEKL performed against the UK Capital Markets industry.
Return vs Market: Insufficient data to determine how BTEKL performed against the UK Market.
Price Volatility
BTEKL volatility | |
---|---|
BTEKL Average Weekly Movement | n/a |
Capital Markets Industry Average Movement | 4.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.2% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: BTEKL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BTEKL's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | n/a | n/a | www.ishares.com/uk/individual/en/products/291450/ |
iShares IV Public Limited Company - iShares NASDAQ US Biotechnology UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. It is managed by BlackRock Advisors (UK) Limited. The fund invests in the public equity markets of the United States.
iShares IV Public Limited Company - iShares NASDAQ US Biotechnology UCITS ETF Fundamentals Summary
BTEKL fundamental statistics | |
---|---|
Market cap | UK£410.60m |
Earnings (TTM) | UK£0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs BTEKL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BTEKL income statement (TTM) | |
---|---|
Revenue | UK£0 |
Cost of Revenue | UK£0 |
Gross Profit | UK£0 |
Other Expenses | UK£0 |
Earnings | UK£0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did BTEKL perform over the long term?
See historical performance and comparison